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Perinatal infection of susceptible mice with the neurotropic retrovirus CasBrE leads to a noninflammatory spongiform 
degeneration of the central nervous system with a long incubation period of up to 1 year. Virus replication in infected 
animals can be suppressed by administration of antiviral antibodies, cytotoxic T cells, or by AZT treatment, which results 
in partial to complete protection from neurological disease. A highly neuropathogenic chimeric retrovirus, FrCas E, which 
contains the envelope gene of CasBrE, induces rapid neurodegeneration within only 16 days. Here we report that this fatal 
disease could be prevented if a nonneuropathogenic Friend murine leukemia virus was administered to mice prior to their 
infection with FrCas E. This double inoculation led to a substantial reduction of the "replication level of FrCas E in spleen and 
CNS. Only live but not heat-inactivated nonneuropathogenic virus was able to protect from FrCasE-induced neurological 
disease. The extent of protection was influenced by the viral envelope gene and the kinetics of replication of the nonneuro- 
pathogenic virus. These observations in addition to the rapidity of the effect make it likely that competition for replication 
sites through the mechanism of viral interference is responsible for the protection. Resistance was demonstrable in vivo 
even when the "protecting" and "challenge" virus belonged to different in vitro interference groups. However, the protection 
was considerably weaker than that seen between viruses belonging to the same interference group. © 1995 Academic 
Press, Inc. 
INTRODUCTION 
Prevention of retroviral infection has been attempted 
through immunological (Hoffman et aL, 1984; Earl et aL, 
1986), pharmacological (Sharpe et aL, 1987; Mitsuya et 
aL, 1990; Robbins etaL, 1989), and genetic (Joshi etaL, 
1991; Weerasinghe etaL, 1991) approaches. Additionally, 
the phenomenon of viral-receptor interference has been 
used to block retroviral entry into cells (Federspiel et aL, 
1991; Limjoco etaL, 1993). Cell surface receptors play a 
key role for the attachment of the virus to the cell and 
its penetration into the cell (Weiss, 1984). Attachment is 
mediated through binding of the virus envelope protein 
to the corresponding cell surface receptors and once this 
occurrs receptors are blocked (Steck and Rubin, 1966a,b; 
Albritton et aL, 1993). Therefore, infection is restricted at 
the entry stage in a cell which already expresses a re- 
lated viral envelope protein. The phenomenon of viral 
interference was used by Rein (1982) to define function- 
ally different viral receptors utilized respectively by eco- 
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tropic, polytropic, and amphotropic host range groups of 
murine leukemia viruses. The envelope proteins of each 
host range group interfere with infection by another mem- 
ber of the same group, but not with a member of another 
host-range group. 
In vivo, viral receptor interference appears to be re- 
sponsible for certain types of genetic resistance to ret- 
roviral infection. In these cases, the protective effect is 
mediated through expression of endogenous retroviral 
envelope sequences resident in the genome of normal 
mice (Bass inet  aL, 1982), but which are expressed in 
a tissue-specific (Lerner et aL, 1976) and sometimes a 
developmentally regulated fashion (Buller et al., 1989). In 
wild mice the FV-4 gene (Suzuki, 1976) encodes expres- 
sion of an ecotropic envelope protein and has been iden- 
tified in both Asian and Western mouse populations 
(Gardner, 1990). This form of protection has been recapit- 
ulated artificially by production of transgenic mice (Lim- 
joco et aL, 1993) and chickens (Federspiel et al., 1991) 
carrying retroviral envelope genes. Although it is not 
known whether genetic resistance to HIV exists in the 
human population, the phenomenon of viral interference 
has been demonstrated for HIV in vitro (Stevenson et aL, 
1988; Le Guern and Levy, 1992; Hart and Cloyd, 1990). 
Recently, two groups have shown that protection from 
retrovirus-mediated disease of the erythroid lineage 
(both proliferative and cytolytic) can be conferred in vivo 
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by delivering the envelope gene exogenously by a repli- 
cation competent retrovirus (Mitchell and Risser, 1992; 
Oorbin and Sitbon, 1993). We were interested in evaluat- 
ing how general a phenomenon this type of protection 
might be. Here we show that a nonneuropathogenic ex- 
ogenous murine retrovirus (FB29) protected mice from 
spongiform encephalomyelopathy induced by a neurovir- 
ulent retrovirus (FrOasE). The protection was potent, pre- 
venting infection and spread of the pathogenic virus both 
in peripheral organs and in the brain. The efficacy of 
protection depended on the kinetics ofvirus replication 
and spread as well as the nature of the viral envelope 
of the "protecting" virus. 
MATERIALS AND METHODS 
Mice, inoculations, and clinical evaluation 
IRW mice are an inbred strain developed and bred at 
the Rocky Mountain Labs. They are highly susceptible 
to the neurodegenerative disease caused by the wild 
mouse ecotropic retrovirus OasBrE and the chimeric vi- 
ruses derived therefrom (Portis et al., 1990). Mice were 
inoculated either intraperitoneally (ip) or intracerebrally 
(ic) with 30 #1 of virus stocks (7 X 103-7 X 104 focus- 
forming units (FFU) per mouse) or with infected spleen 
cells prepared as previously described (Czub eta/. ,  
1991). 
Mice were observed daily beginning at approximately 
12 days of age, and the experiments were generally ter- 
minated at the age of 40-50 days. Mice were weaned 
at 21 days postpartum. The clinical signs indicative of 
the neurodegenerative disease have been described 
previously (Portis et aL, 1990). They include reflex abnor- 
malities progressing to hind and then forelimb paralysis 
associated with wasting and terminating in convulsive 
episodes (Czub et aL, 1994). Incidence of disease was 
the measure of the frequency of mice consistently exhib- 
iting any of these clinical signs during the respective 
periods of observation. Some inoculated mice exhibited 
subtle and transient reflex abnormalities which were 
sometimes observed, as well, in uninoculated controls. 
For the purposes of the experiments compiled in Table 
2, these mice were considered "protected." incubation 
period was the interval of time between inoculation and 
the day on which the first sign of neurologic disease 
(usually reflex abnormalities) was observed. 
In several experiments mice were scored for the sever- 
ity of clinical disease. The scoring system was identical 
to that described previously (Czub eta/., 1994)= 1 ÷, mild 
intention tremor and abnormal abduction reflex; 2+, pa- 
resis and jerky gate; 3% wasting and paralysis; and 4+, 
preterminal disease with immobility and episodes of sei- 
zure-like activity. Mice were generally euthanized at 
stage 4+. 
Viruses 
FB29 is a molecular clone of the 1-5 strain of Friend 
MuLV (Sitbon eta/., 1986). After neonatal inoculation, 
FB29 causes hemolytic anemia at 2-3 weeks of age 
followed by erythroleukemia at 3-4 months (Sitbon et 
aL, 1986). FB29 infects the brain but does not induce 
neurological disease (Portis eta/., 1990). 15-1 is a molec- 
ular clone of CasBrE (Portis et al., 1990), a strain of wild 
mouse eootropio retrovirus which, after neonatal inocula- 
tion, causes neurodegenerative disease at low inci- 
dence, with a long incubation period of ~>6 months. 
FrOas E is a chimeric virus consisting of the envelope 
gene and 3' pol sequences from CasBrE (Sphl-Clal frag- 
ment) introduced into the genome of FB29 (Portis et al., 
1990). Thus, the name of the virus designates a Friend 
MuLV (Fr) containing the Casitas virus (Cas) envelope 
gene (superscript E). FrCas E is highly neurovirulent after 
neonatal inoculation and causes neurologic disease with 
an incubation period of only 16 days (Czub et al., 1992). 
The chimeric Friend MuLV 04-87 (Sitbon et al., 1986) 
was kindly provided by Dr. Marc Sitbon, Hopital Cochin, 
INSERM, Paris). This virus consists of the genome of 
FB29 into which was introduced the Sphl -C la l  fragment 
(3' pol and env) from the weakly hemolytic Friend MuLV 
variant B3. Like B3, 04-87 is only weakly hemolytic. 
Fr98 E is a chimeric virus constructed by an approach 
identical to that used for the generation of FrCas E (Portis 
et al., 1990). That is, we introduced 3' pol and env se- 
quences from a neurovirulent polytropic retrovirus 98D 
(Buller eta/., 1990) into the genome of FB29 from an Sphl 
site at position 5135 to a Clal site at position 7702 of 
FB29 (Perryman eta/., 1991). The molecular clone of the 
virus 98D was provided by Bruce Chesebro (Rocky Moun- 
tain Laboratories, Hamilton, Montana) and the details of 
the cloning of its genome will be presented elsewhere. 
The chimeric virus Fr98 E is neurovirulent after neonatal 
inoculation, but the clinical disease was observed only 
after an incubation period of 30-40 days, in contrast to 
that caused by FrOas E which is seen after an incubation 
period of 16 days. In addition, the diseases are distin- 
guishable clinically (see legend Table 1). An overview of 
all viruses used in this study is shown in Tables 1A 
and 1B. 
The titers of virus stocks ranged from 2 × 105 to 2 
x 106 focus-forming units/ml as determined by a focal 
immunoassay described elsewhere (Czub et aL, 1991). 
Infectious center assays were performed as described 
previously (Czub et al., 1991). Viremia titers were per- 
formed on serum samples collected from mice at various 
times after inoculation as described previously (Czub et 
a/., 1992). Heat inactivation was carried out by incubation 
of an aliquot of the FB29 virus stock at 56 ° for 10 min. 
This treatment reduced the virus titer by ~>10S-fold (Czub 
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TABLE 1 
CHARACTERISTICS OF VIRUSES 
Neurological 
A. Virus a Host range disease b 
FB29 ecotropic - 
CasBrE ecotropic + 
B3-20 ecotropic - 
FM CF-98D polytropic + + 
Genome structurel 
Neurological 
B. Virus Host range env LTR/gag/pol disease 
FrCas E ecotropic CasBrE FB29 +÷++d 
C4-87 ecotropic B3-20 FB29 
Fr98 E polytropic FMCF-98D FB29 ÷+ 
Parental viruses are shown in A. Chimeric viruses are shown in B. 
Sources and/or derivation of each virus are described under Materials 
and Methods. 
b The severity of neurological disease is designated arbitrarily by + 
to +÷++. 
°The genome structure is shown in two parts corresponding to seg- 
ments defined by an Sphl site near the 3' end of the pol gene and a 
Clal site near the 3' end of the env gene (Portis et aL, 1990; Sitbon et 
aL, 1986). The Sphl-Clal segment, thus, encompasses 3' pol se- 
quences and the bulk of the env gene (designated env in the table). 
#The neurological diseases induced by FrCas E and Fr98 E can be 
distinguished both clinically and based on their respective tempos. 
FrOas E induces a fatal neurological disease characterized by tremor 
and paralysis with a short incubation period of 16 days. Fr98 E causes  
a disease characterized by disequilibrium with a longer incubation 
period of 30-60 days. 
et aL, 1991). All titrations were carried out on M. dunni  
cells (Lander and Chattopadhyay, 1984). 
Southern blot analysis 
DNA from spleen and brain was extracted as de- 
scribed previously (Portis eta/., 1990). DNAwas digested 
with BamHI, which excises a 3.4-kb internal fragment 
from FrOas E and a 0.8-kb fragment from FB29 detected 
by probes WM xB or PE57BS, respectively (Portis et al., 
1990). DNA was fractionated in 1% agarose gels, blotted 
onto nitrocellulose paper, and hybridized with the appro- 
priate probe labeled with [32p]dCTP using the random 
prime technique (Boehringer-Mannheim). Washing con- 
ditions and autoradiography have been previously de- 
scribed (Portis et aL, 1990). 
RESULTS 
FB29 protected 100% of mice from neurologic 
disease induced by FrCas E 
Since the disease induced by FrCas E has such a short 
course and is so predictable in its presentation and 
tempo (Czub eta/., 1994), it provided a convenient model 
with which to ask whether prior infection with FB29, one 
of the ecotropic parents of FrCas E, might modulate the 
disease course. FB29 infects both nonneuronal tissues 
as well as the brain, but does not induce neurologic 
disease (Portis et al., 1990). Seventeen IRW mice were 
inoculated with 7 x 104 FFU of FB29 ip at 1 day postpar- 
tum (P1), followed on P4 with 1 X 104 FFU of FrCas E. To 
our surprise, none of these mice exhibited neurological 
signs over an observation period of 50 days (Table 2, 
No. 7). From the control group inoculated with FrCas E 
alone on P4, all nine animals exhibited the typical FrCas E- 
induced neurological signs with a mean incubation pe- 
riod of 17 days postinoculation (pi) (Table 2, No. 3), and 
reached the terminal stage within 21 days pi (not shown). 
Thus, inoculation of a nonneuropathogenic retrovirus 
completely protected the mice from the neurodegenera- 
tive effects of FrCas E, 
In order to ask whether it was necessary for the protec- 
tive virus to be replication competent, FB29 was heat- 
inactivated prior to inoculation. No protection was ob- 
served (Table 2 No. 14). We were also interested in de- 
termining whether the early hemolytic effect of FB29 
(Sitbon et aL, 1986) might in some way be responsible 
for its protective effect, perhaps by eliminating target 
cells for FrCas E. The chimeric virus C4-87 consists of the 
genome of FB29 containing the envelope gene of an 
essentially nonhemolytic ecotropic virus (B3) (Sitbon et 
aL, 1986) (Table 1B). This virus was just as effective as 
FB29 at protecting mice (Table 2 No. 15). 
FB29 restricted infection by FrCas E in both spleen 
and brain 
The relative levels of FB29 and FrCas E viral DNA in 
spleen and CNS of doubly infected mice 16 days after 
FrCas E inoculation were determined by Southern blot 
analysis (Fig. 1). As has been shown previously, both 
FB29 and FrCas E, when inoculated alone at P1 or 2, 
infected the CNS and spleen at comparable levels (Portis 
et aL, 1990). After double infection with the two viruses 
(FB29 on P1 and FrCas E on P4), however, viral DNA from 
FrOas E could neither be detected in spleen nor in CNS 
(Fig. 1A). In contrast, analyzing the same animals, the 
levels of FB29 viral DNA was high in both spleen and 
CNS (Fig. 1B). These results show that an ip infection 
with FB29 protected brain and spleen from infection with 
the neuropathogenic virus FrOas E. 
Since, in these experiments, virus was always inocu- 
lated intraperitoneally, it is possible that FB29 blocked 
replication of FrCas E only in peripheral organs but not in 
the CNS. Therefore, in an attempt to bypass the restric- 
tion to FrCas E infection in mice previously infected ip 
with FB29 (at P1), we inoculated groups of mice with 
FrOas E intracranially on P4. None of these nine animals 
exhibited neurological signs within 41 days pi (Table 2, 
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TABLE 2 
DOUBLE INOCULATIONS WITH VARIOUS MuLV's 
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Time of inoculation a (days of age) 
Incidence 
Expt No. 1 2 3 4 6 % 
of disease 
(n) 
Incubation period 
(days _+ SD) 
1 FrCas E 1 O0 (95) 
2 FrCas E 100 (10) 
3 FrCas E 1 O0 (9) 
4 FrCas E 1 O0 (37) 
5 FrCas E (spleen) '~ 100 (3) 
6 FB29 FrOas E 0 (10) 
7 FB29 FrCas E 0 (17) 
8 FB29 FrCas E (ic) e 0 (9) 
9 FB29 FrCas E (spleen) b 0 (7) 
10 FB29 FrCas E 30 (1 O) 
11 FB29 FrCas E 14 (7) 
12 FB29 + FrCas E 78 (9) 
13 FB29 + FrCasE(ic)e 90 (10) 
14 FB29 + (10' 55°) f FrCas E 100 (11) 
15 C4-87 FrCas E 0 (11) 
16 Fr98 E FrCas E 100 (27) 
17 Fr98 E FrOas E 100 (7) 
18 CasBrE FrCas E 1 O0 (12) 
17+2 
15_+1 
17+1 
14 - 72 
23-+ 1 
NNS ~ 
NNS ° 
NNS ~ 
NNS ° 
21-+5 
26_+6 
20-+2 
15-+2 
15_+2 
NNS c 
18+3 
26_+2 
14_+1 
a Unless otherwise indicated, all inoculations were by the intraperitoneal route. 
One million spleen cells from an FrCasE-infected mouse (containing 2.7 x 103 virus-producing cells) were injected ic. 
c No neurological signs over an observation period of 50 days. 
No neurological signs over an observation period of 41 days. 
e Intracerebral inoculation. 
FB29 was heat-inactivated. 
No. 8). Furthermore, one group of FB29-infected mice 
was inoculated on P4 intracranially with 10 e FrOasE-in - 
fected spleen cells containing 2.7 x 103 virus-producing 
cells (as determined by infectious center assay). None 
of these animals developed neurological signs within a 
50-day period of observation (Table 2, No. 9). These re- 
sults suggest that cells from both peripheral organs and 
the CNS were protected from FrCas E superinfection 
when previously infected with FB29. 
Onset of protection by FB29 was rapid 
The time interval between FB29 and FrCas E inoculation 
was a determinant of the degree of protection. This is 
shown in Table 2, Nos. 10-13. Mice were inoculated 
with FB29 on P1 and FrCas E on either P3, 2, or 1. None 
of these mice showed the degree of protection seen in 
mice inoculated with FrCas E on P4 or later (Table 2, Nos. 
6 and 7). However, even in mice inoculated with both 
FB29 and FrOas E on the same day (P1) 3 of 19 were 
protected (Table 2, Nos. 12 and 13). This compares to 
0/95 protected in the group receiving FrOas E alone on 
P1 (Table 2, No. 1). Furthermore, the severity of disease 
in the affected mice inoculated with both viruses on the 
same day was generally lower than in mice inoculated 
with FrOas E alone (not shown). Cumulatively, these re- 
suits indicate that the protection resulting from inocula- 
tion of FB29 was rapid in onset and by 4 days, was 
essentially complete. 
Protection appeared to be mediated by viral 
interference 
Murine and avian retroviruses have been divided into 
host-range groups based on viral interference patterns 
(Weiss, 1984). Thus, murine ecotropic viruses interfere 
with superinfection by other ecotropic viruses but not by 
polytropic viruses, since the two host range groups use 
different receptors in vitro (Rein, 1982). This receptor 
specificity is determined by the viral envelope glycopro- 
tein. If viral interference was responsible for the protec- 
tive mechanism described herein, it should obey the 
rules of viral interference demonstrated originally for 
MuLV by Rein (1982). To test this hypothesis in vivo we 
used the chimeric retrovirus Fr98 E containing the enve- 
lope gene of the polytropic virus FMCF98D (Buller et 
aL, 1990) on an FB29 background (Table 1B). This virus 
exhibited the polytropic host range of FMCF98D in that 
it infected both mouse and mink 00L64 cells in vitro (not 
shown). 
Fr98 E, after neonatal inoculation, infects the CNS and 
causes a neurological disease within 30-60 days, which 
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FB29 P1 /  
F rCas  E P4  F rOas  E P4 
I If t 
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3.4kb 
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FIG, 1. Southern blot for viral DNA in spleen and brain of mice inocu- 
lated with two ecotropic viruses. Mice were either inoculated with 
FrCas E on P4 or with FB29 on P1 and then FrCas E on P4. Mice were 
killed on P20 and 10 #g of BamHI-digested DNA from either spleen 
(S) or CNS (C) fractionated on a 1% agarose gel and transferred to 
nitrocellulose, The numbers represent individual mice (three mice per 
group). The Southern blot was probed first with WM x~ (Portis et aL 
1990) for detection of FrOas E envelope sequences (3.4-kb band) (A) 
and subsequently with pE57BS for detection of FB29 envelope se- 
quences (0.8-kb band) (B). Preinoculation of FB29 prevented infection 
of both the spleen and brain with FrOas E. 
is clinically distinct from that caused by FrCas E (see the 
legend to Table 1). In double inoculation experiments, 
Fr98 E was inoculated into IRW neonates either 2 days 
(Table 2, No. 16) or 3 days (Table 2, No. 17) prior to 
FrOas E. The majority of these mice developed the typical 
FrCas E disease. However, in the group with a 3-day inter- 
val between inoculations there was a noticeable length- 
ening of the incubation period (compare Table 2, Nos. 3 
and 17) and, as shown in Fig. 2, the clinical disease was 
also milder compared to mice receiving only FrCas E on 
P4. Consistent with these clinical observations, Southern 
blot analysis (Fig. 3) indicated that Fr98 E restricted infec- 
tion of the brain by FrCas E. Interestingly, however, unlike 
FB29 (Fig. 1), Fr98 E did not appear to affect the level 
of FrOas E viral DNA detected in the spleen at 16 days 
postinoculation. Thus, although these results showed 
that the efficiency of protection in vivo was dependent 
on the nature of the viral envelope gene, the env-gene 
specificity of the phenomenon was not absolute. 
Protection was dependent on kinetics of virus 
replication 
Since protection appeared to be mediated by viral in- 
terference, one would expect all ecotropic retroviruses 
4+. 
"0 
3+- 
(.9 
.c  2+, 
~ 1+. 
0 , 
10 15 20 
m/e.<..• Fr E[p4] Fr98 E P1 . /o  
/ FS29[m] 
0 I ~ FrCasE[p4] 
2~ 3~ 3~ 46 4 56 s~ 
Days postinoculation 
FIG. 2. Severity of clinical neurologic disease followed as a function 
of time after inoculation of FrCas ~. One group (n = 7) was inoculated 
with Fr98 E on P1; one group (n = 8) was inoculated with FB29 on P1; 
and one group (n = 8) was uninoculated on P1, All mice were chal- 
lenged with FrCas E on P4. Mice were followed for clinical disease and 
scored according to the grading system described under Material and 
Methods. Fr98 E induced partial protection from FrOasE-induced clinical 
disease, though not as potent as that afforded by FB29. Clinical signs 
of neurologic disease in the group inoculated with FB29 on P1 were 
marginal at best and were transient, consisting only of a slight abduc- 
tion reflex abnormality of the hind limbs without tremor. When in doubt, 
however, mice were classified as Grade 1 +. 
to behave like FB29 and produce strong protection. How- 
ever, this was not the case. The ecotropic virus CasBrE 
was nonprotective (Table 2, No. 18), a result which was 
particularly puzzling, since the envelope gene used to 
construct FrCas E was obtained from CasBrE (Portis et 
al., 1990). The explanation of this apparent conundrum 
FrCasE P4 Fr98 E P1/FrCas ~ P4 
[ II I 
1 2 3 1 2 3 
S C S C S C  SOS CS  C 
3.4kb - 
FIG. 3. Southern blot for viral DNA in spleen (S) and ONS (C) of 
mice inoculated with viruses of different host range, Mice were either 
inoculated with FrCas E on P4 or with Fr98 E on P1 followed by FrCas E 
on P4. Blots were carried out as described in the legend to Fig. 1 
and were probed only with WM x8 for detection of FrCas E envelope 
sequences (3.4 kb). Note that in the mice inoculated with Fr98 E, FrCas E 
viral DNA was not detected in the brains, whereas that in the spleens 
was comparable to the mice inoculated with FrOas E alone, 
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FIG. 4, Viremia kinetics in mice inoculated with either FrCas E or Fr98 E 
on P1. Each point represents the mean and the error bars one standard 
deviation about the mean for four mice per group. Viremia kinetics 
during the first 8 days after inoculation were comparable. 
came from a consideration of the kinetics of replication 
of these viruses. CasBrE replicates slowly after neonatal 
inoculation, reaching peak viremia titers by 8-9 days 
postinoculation (Czub eta/. 1992). In contrast, FB29 ex- 
hibits rapid replication kinetics reaching peak viremia 
titers by 4-5 days postinoculation (Czub et al. 1992). At 
this time, viremia titers plateau, suggesting that most or 
all peripheral cells that will productively replicate virus 
are infected during this period. FrOas E, which contains 
the LTR, gag and 5' pol genes from FB29 (Table 1B), 
also displays rapid replication (Czub et a/. 1992). These 
observations suggest that a pool of susceptible cells 
could be infected by either FB29, 15-1, or FrCas E. The 
fraction of this pool which was infected during the first 
few days after inoculating the "protective" virus would 
depend on the kinetics of its replication and spread be- 
fore inoculation of FrOas E. This explanation, however, 
cannot explain the ineffective protection afforded by 
Fr98 E. After neonatal inoculation (P1), this virus reached 
peak viremia titers within 4-5 days, similar in tempo to 
both FrOas E (Fig. 4) and FB29 (Czub et a/. 1992). 
DISCUSSION 
The protection from retrovirus-mediated disease dem- 
onstrated in this study was potent and rapid in onset. A 
role for immunity appears unlikely for severai reasons. 
Neonatal inoculation of mice with MuLVs generally does 
not lead to virus-specific immunity (Klement et al. 1976; 
Portis, 1990) or is weak at best (Nagra eta/., 1993), Fur- 
thermore, a time interval of only 3 days between the two 
viruses was sufficient to gain complete protection and 
partial protection was even seen when the viruses were 
inoculated on the same day. This time frame would not 
be sufficient to generate a protective immune response. 
Among virus-inducible cytokines, tumor necrosis factor- 
(Wong et al., 1988) and interferon-7 are known to ex- 
hibit direct antiretroviral activities without involvement of 
the immune system (Pitha et al., 1976; Robbins et aL, 
1989; Sarzotti eta/., 1993). IFN-~ production in mice has 
been observed in response to MuLV infection only of 
adult but not of neonatal mice (Sarzotti eta/., 1993). It is, 
thus, unlikely that IFN-?, is involved in the double infec- 
tion I~rotection process. In addition, protection went 
along with persistent infection by the "protective" virus 
(Fig. 1) (Corbin and Sitbon, 1993). It is difficult o reconcile 
a role for cytokines or other antiviral host defenses in 
combatting only the challenge virus. Among mechanisms 
conferring selective resistance to retrovirus replication 
at the cellular level (Federico et al., 1993; Gorska-Flipot 
eta/., 1992; Taddeo et al., 1993; Trono et al., 1989) viral 
receptor interference is best in accordance with the re- 
sults presented herein. 
A critical indicator of viral interference is the depen- 
dence of the protection on the nature of the viral envelope 
gene. The envelope gene determines the host-range of 
the virus (i.e., ecotropic, amphotropic, polytropic). Since 
each host-range group utilizes a different receptor, viral 
interference is generally seen only among viruses be- 
longing to the same host-range group. Two previous 
reports on this subject (Mitchell and Risser, 1992; Corbin 
and Sitbon, 1993) demonstrated the protective effect of 
nonpathogenic ecotropic murine retroviruses on the 
erythroproliferative disease caused by Friend spleen fo- 
cus-forming virus pseudotyped with an ecotropic helper 
virus. As would be expected if viral interference was 
responsible for the protection in those studies, protection 
was afforded only by ecotropic viruses and not by viruses 
of other host-range groups (Mitchell and Risser, 1992; 
Corbin and Sitbon, 1993). In the current study, however, 
we observed essentially no protection from FrCasE-in -
duced neurologic disease by prior inoculation of CasBrE, 
the ecotropic virus from which the envelope gene of 
FrCas E was derived (Portis et al., 1990). In this case, 
the lack of protection correlates with the rather sluggish 
replication kinetics of CasBrE compared to the rapid ki- 
netics of FrOas E (Czub eta/., 1992). Sequences which 
influence the kinetics of replication have been localized 
to the viral LTR (Portis eta/., 1990) and 5' leader se- 
quence (Portis eta/., 1994). Thus, the efficiency of spread 
of the "protective" virus appears to be an important deter- 
minant of its efficacy. 
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In the current study we evaluated theenv  gene speci- 
ficity of protection with a chimeric virus Fr98 E which car- 
ries the envelope gene of the polytropic virus FMCF98D 
on an FB29 background. This virus exhibited the same 
rapid viremia kinetics after neonatal inoculation as did 
FrCas E and FB29. Yet, compared to FB29, Fr98 E was only 
weakly protective. Thus, in this case the nature of the 
viral envelope gene was clearly a determinant of the 
efficacy of the "protective" virus, consistent with the no- 
tion that receptor blockade was responsible for the pro- 
tection. 
Despite the fact that all mice treated with Fr98 E devel- 
oped neurologic disease after FrOas E infection, Fr98 E in- 
duced partial resistance both in terms of lengthening the 
incubation period of the neurologic disease and modulat- 
ing its severity. Furthermore, Fr98 E appeared to restrict 
infection by FrOas E, specifically in the brain but appar- 
ently not in the spleen. In NIH3T3 cells in vitro it is clear 
that polytropic and ecotropic viral receptors are function- 
ally distinct. Viruses carrying either polytropic envelope 
proteins or chimeric envelope proteins consisting of 
combinations of polytropic and amphotropic sequences 
do not interfere with superinfection by ecotropic virus 
infection (Ott and Rein, 1992). 
The in vivo studies can be interpreted in at least two 
ways. At face value the organ specific nature of the re- 
striction mediated by Fr98 E would suggest that the eco- 
tropic receptors in the spleen and brain are different, 
Fr98 E being capable of blocking the brain but not the 
spleen receptor. There is evidence for heterogeneity of 
ecotropic receptors in brain capillary endothelial cells of 
the rat (Masuda et aL, 1993), but it is not yet clear whether 
this reflects heterogeneity of receptor genes or differen- 
tial post-translational modification in specific cell types. 
An alternative explanation does not require the existence 
of ecotropic receptor heterogeneity. Czub et al. (1992) 
showed that the brain develops a resistance to infection 
as a function of time after birth, whereas peripheral or- 
gans, such as the spleen, maintain their susceptibility to 
FrOas E (Czub et al., 1991, 1992). It is only necessary to 
slow the kinetics of replication of FrOas E in the periphery 
to restrict its access to the brain. The Southern blot 
shown in Fig. 3 is precisely the picture seen in mice 
which are inoculated with FrCas E alone but on P6-10 
instead of P1 (Czub et al., 1992). The fact that viral DNA 
was not detected in the brains of these mice likely re- 
flects the relative insensitivity of the assay since all of 
the mice eventually developed neurological disease 
characteristic linically of that caused by FrOas E. Slowing 
the spread of FrOas E could be accomplished in one of 
two ways. The polytropic envelope protein may interact 
weakly with the ecotropic receptor. This has not been 
observed in vitro but cannot presently be ruled out. Alter- 
natively, the genome of FrOas E may be preferentially 
packaged in the envelope protein of Fr98 E. This would 
restrict spread of the pseudotyped virus due to blockade 
of polytropic receptors by the Fr98 E envelope protein. 
Viral interference through expression of endogenous 
retroviral envelope genes appears to be a resistance 
mechanism which has evolved in diverse feral mouse 
populations (Gardner, 1990). Although the resistance in 
wild mice is essentially complete, the efficiency of 
protection afforded by these genes introduced as 
transgenes appears to be associated with the level and 
perhaps localization of envelope gene expression in the 
host (Federspiel et al., 1991; Limjoco et aL, 1993). Intro- 
duction of these protective envelope genes using a repli- 
cation competent virus is a novel approach to dissemi- 
nating the protective gene through the susceptible popu- 
lations of cells in the host. We have shown here that the 
kinetics of replication of the protective virus as well as 
the nature of theviral envelope gene are critical determi- 
nants of efficacy. In addition, the current study has dem- 
onstrated that this form of viral resistance is not restricted 
to the erythroid lineage but is effective in the central 
nervous system as well. In view of the recent discussion 
of the possible use of gene therapy to restrict H IV replica- 
tion (Sawer and Rossi, 1993), the induction of viral inter- 
ference, which would prevent virus entry through expres- 
sion of the HIV envelope gene (Berencsi et al., 1989), 
might be worthy of consideration. Potential pitfalls to this 
idea are, (1) pseudotypic mixing might expand the host 
range of HIV (Le Guern and Lew, 1992). This could be 
avoided by using a defective envelope protein. (2) Ex- 
pression of the viral envelope protein might subvert the 
normal function of the virus receptor. In the case of the 
receptor for ecotropic MuLV, which is a transporter for 
cationic amino acids (Kim eta/., 1991; Wang etaL, 1991), 
binding of viral envelope protein has been shown to alter 
its glycosylation (Kim and Cunningham, 1993) and is as- 
sociated with a -50% reduction of amino acid transport 
(Wang et al., 1992; Kim and Cunningham, 1993). Never- 
theless, the FV4 gene has emerged as a potent resis- 
tance mechanism in wild mice and perhaps is offering 
an important evolutionary lesson. 
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